ES2108149T3 - Derivado de cefalosporina. - Google Patents

Derivado de cefalosporina.

Info

Publication number
ES2108149T3
ES2108149T3 ES93103957T ES93103957T ES2108149T3 ES 2108149 T3 ES2108149 T3 ES 2108149T3 ES 93103957 T ES93103957 T ES 93103957T ES 93103957 T ES93103957 T ES 93103957T ES 2108149 T3 ES2108149 T3 ES 2108149T3
Authority
ES
Spain
Prior art keywords
group
bacteria
various
tiazolyltium
oxazolylite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93103957T
Other languages
English (en)
Inventor
Masaki Tsushima
Katsuyoshi Iwamatsu
Atsushi Tamura
Seiji Shibahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Application granted granted Critical
Publication of ES2108149T3 publication Critical patent/ES2108149T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN DERIVADO DE AMINOTIAZOLILRINA REPRESENTADO POR LA SIGUIENTE FORMULA GENERAL (I) QUE TIENE UN GRUPO TIO DE ANILLO CONDENSADO COMO GRUPO SUSTITUYENTE EN POSICION 3 QUE CONTIENE UN GRUPO TIAZOLILTIO, UN GRUPO OXAZOLILTIO O UN ANILLO HETEROCICLICO DEL MISMO COMO UNO DE LOS COMPONENTES DEL ANILLO. SEGUN LA PRESENTE INVENCION EL COMPUESTO TIENE UNA EXCELENTE ACTIVIDAD PARA INHIBIR EL DESARROLLO DE DIVERSAS BACTERIAS, ESPECIALMENTE LA BACTERIA GRAM-POSITIVA INCLUIDO EL STAPHYLOCOCCUS AUREUS (MRSA) RESISTENTE A LA METICILINA Y, POR TANTO, EL AGENTE ANTIBACTERIANO QUE COMPRENDE COMO INGREDIENTE ACTIVO EL COMPUESTO DE LA INVENCION, SE PUEDE UTILIZAR COMO FARMACO TERAPEUTICO PARA EL TRATAMIENTO DE DIVERSAS INFECCIONES BACTERIANAS.
ES93103957T 1992-03-12 1993-03-11 Derivado de cefalosporina. Expired - Lifetime ES2108149T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4053885A JP2857532B2 (ja) 1992-03-12 1992-03-12 新規セファロスポリン誘導体

Publications (1)

Publication Number Publication Date
ES2108149T3 true ES2108149T3 (es) 1997-12-16

Family

ID=12955194

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93103957T Expired - Lifetime ES2108149T3 (es) 1992-03-12 1993-03-11 Derivado de cefalosporina.

Country Status (5)

Country Link
US (1) US5607927A (es)
EP (1) EP0560365B1 (es)
JP (1) JP2857532B2 (es)
DE (1) DE69314072T2 (es)
ES (1) ES2108149T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455239A (en) * 1993-08-05 1995-10-03 Merck & Co. Inc. 3-aryl of heteroaryl-7-heteroaralkylamido cephalosporin compounds, compositions and methods of use
US5496816A (en) * 1994-03-14 1996-03-05 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
US5698547A (en) * 1994-04-01 1997-12-16 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
US5593986A (en) * 1994-04-01 1997-01-14 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
US5688786A (en) * 1994-04-01 1997-11-18 Microcide Pharmaceuticals, Inc. β-lactam antibiotics
US5498777A (en) * 1994-07-20 1996-03-12 Merck & Co., Inc. 3-thioheteroaryl cephalosporin compounds, compositions and methods of use
US5565445A (en) * 1995-02-22 1996-10-15 Merck & Co., Inc. 3-thioheteroaryl 1-carba-1-dethiacephalosporin compounds, compositions and methods of use
IN184690B (es) * 1996-03-18 2000-09-23 Ranbaxy Lab Ltd
EP1090920A4 (en) * 1998-06-24 2001-11-07 Zenyaku Kogyo Kk OPPOSES CEPHEM
CN101143870B (zh) * 2006-09-12 2010-09-08 山东轩竹医药科技有限公司 头孢菌素衍生物
CN101190922B (zh) * 2006-12-01 2010-06-02 山东轩竹医药科技有限公司 头孢菌素衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605997A5 (es) * 1974-08-30 1978-10-13 Ciba Geigy Ag
US3992377A (en) * 1974-12-13 1976-11-16 Eli Lilly And Company 3-Thio-substituted cephalosporin antibiotics
EP0009008A3 (de) * 1978-09-08 1980-05-14 Ciba-Geigy Ag Cephalosporinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4812562A (en) * 1985-07-25 1989-03-14 Taisho Pharmaceutical Co., Ltd. Cephalosporin derivatives
IL100576A (en) * 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
US5247073A (en) * 1991-01-18 1993-09-21 Eli Lilly And Company 7-(Amino or protected amino)-3-thioheterobicyclic cephalosporins
JPH05132488A (ja) * 1991-08-13 1993-05-28 Meiji Seika Kaisha Ltd 新規セフアロスポリン誘導体

Also Published As

Publication number Publication date
EP0560365A1 (en) 1993-09-15
JPH05255345A (ja) 1993-10-05
JP2857532B2 (ja) 1999-02-17
DE69314072T2 (de) 1998-05-07
US5607927A (en) 1997-03-04
EP0560365B1 (en) 1997-09-24
DE69314072D1 (de) 1997-10-30

Similar Documents

Publication Publication Date Title
MX9303158A (es) Derivados de aminoquinolona substituidos con grupoarilo o con un grupo heterociclico aromatico; y agente anti-vih.
AR024077A1 (es) Compuestos antibacterianos
BRPI0411016A (pt) composições antisépticas, processos e sistemas
ES2108149T3 (es) Derivado de cefalosporina.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
PA8489501A1 (es) Antibioticos cetolidos
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituìdos"
ATE294185T1 (de) Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
PY0000170A (es) 2-(hydroxyo-n-(5-nitor-2-thiazolyl) benzamide
UY25780A1 (es) Nuevos antibióticos macrólidos
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
BRPI0413964A (pt) ácido derivado do ácido carboxìlico quinolona, sua composição e agente antibacterial
MX9100607A (es) Compuesto triciclico novedoso o sales del mismo,metodo para producir el mismo y agente antimicrobiano que lo contiene
MX2020000576A (es) Compuestos quimicos.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
MX2018001022A (es) Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.
AR039727A1 (es) Difluorotioacetamidas de oxazolidinonas como agentes antibacterianos y composicion farmaceutica en base a ellas
MX2020011367A (es) Compuesto oxo-sustituido.
AR019482A1 (es) DERIVADOS SUSTITUIDOS DEL 2-IMIDAZO(5,1-b)TIAZOL-CARBAPENEM, LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y EL USO DE DICHOS DERIVADOS PARA LAPREPARACION DE MEDICAMENTOS
BRPI0317188A2 (pt) Novo derivado de 2,4-diamino-1,3,5-triazina
IL57853A0 (en) Pseudotrisaccharides,their production and their use as medicaments
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
ES2128404T3 (es) Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 560365

Country of ref document: ES